Heart Failure (HF) is a common disease that affects an estimated global population of over 40 million. It is the most frequent cause of hospitalizations in patients over the age of 65, placing a considerable financial and social burden on patients, healthcare providers, and care providers. Accurate clinical assessment of HF and cost-effective management strategies are critical in improving patient outcomes and reducing the socioeconomic burden of this disease.

In this podcast episode, we will have a conversation between Dr. Christopher deFilippi, a cardiologist at the Inova Heart and Vascular Institute, and Dr. Ivan Salgo to learn more about heart failure, how it is diagnosed, and the value of using the in-vitro diagnostic test NT-proBNP.

 

About our Speaker:

Dr. Christopher deFilippi is a distinguished cardiologist who currently works at the Inova Heart and Vascular Institute (IHVI) in Fairfax, Virginia as the Vice-Chair of Academic Affairs.

In his oversight of clinical research, he has built IHVI to be a national leader in site-based research. He serves on the Editorial boards of Circulation, JACC, and JACC: Heart Failure. He is an Associate Editor for the Journal of Applied Laboratory Medicine. His research is focused on evaluating in-vitro diagnostics and proteomics discovery for diagnosis, prognosis, and therapy guidance across the spectrum of health from detection of preclinical cardiovascular disease to diagnosis and treatment in the critically ill.